API
< Back to all clusters
[HEALTH] · Australia, United States · 4 sources

started · updated

Science Corporation retinal chip enables patient to read

A patient suffering from Stargardt disease, a hereditary condition that causes progressive loss of central vision, has successfully regained the ability to read words using a subretinal implant called PRIMA. Developed by Science Corporation, the device is a tiny chip measuring approximately 2 x 2 millimeters and 30 microns in thickness.

The implant was surgically placed beneath the retina at the Sydney Eye Hospital in Australia. The technology works by using 378 photovoltaic pixels to convert light into electrical signals, which are then picked up by the patient's remaining functional retinal cells. To facilitate vision, the patient wears specialized glasses equipped with a camera that projects infrared light onto the chip, allowing for image magnification between 1 and 12 times.

During the initial rehabilitation sessions, the patient first distinguished a single letter and subsequently successfully read a complete word. While the device has received CE marking in the European Union for geographic atrophy, it currently holds humanitarian device designation from the FDA in the United States rather than full approval. The clinical application for Stargardt disease is part of the PRIMAria trial supervised by Dr. Matthew Simunovic.

Entities

FDA · Matthew Simunovic · Max Hodak · Science Corporation · Stargardt disease · Sydney Eye Hospital